Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA (guselkumab) in ulcerative colitis. The decision supports a 400 mg subcutaneous induction regimen at weeks 0, 4 and 8 for adults with moderately to severely active disease. The subcutaneous option offers an alternative to intravenous administration, with studies indicating patient preference for SC delivery. The CHMP opinion follows EC approval of guselkumab for UC in April 2025 and its approval in CD in May 2025. If adopted, the new regimen will offer physicians greater flexibility in tailoring treatment for patients with inflammatory bowel disease.